INT108823

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.47
First Reported 2003
Last Reported 2009
Negated 2
Speculated 0
Reported most in Abstract
Documents 8
Total Number 8
Disease Relevance 4.06
Pain Relevance 4.14

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

mitochondrion (COX5A) small molecule metabolic process (COX5A)
Anatomy Link Frequency
vasculature 1
platelets 1
COX5A (Homo sapiens)
Pain Link Frequency Relevance Heat
cINOD 35 99.78 Very High Very High Very High
aspirin 9 99.66 Very High Very High Very High
cva 3 99.06 Very High Very High Very High
Potency 5 98.84 Very High Very High Very High
Pain 2 96.72 Very High Very High Very High
Neuropathic pain 1 96.52 Very High Very High Very High
Inflammation 5 96.36 Very High Very High Very High
Arthritis 1 92.16 High High
Hyperalgesia 1 89.12 High High
COX-2 inhibitor 9 83.20 Quite High
Disease Link Frequency Relevance Heat
Cv General 3 Under Development 3 99.06 Very High Very High Very High
INFLAMMATION 14 98.16 Very High Very High Very High
Heart Rate Under Development 2 97.64 Very High Very High Very High
Pain 2 96.72 Very High Very High Very High
Neuropathic Pain 1 96.52 Very High Very High Very High
Pressure And Volume Under Development 3 96.44 Very High Very High Very High
Hypertension 3 96.16 Very High Very High Very High
Cancer 2 94.76 High High
Arthritis 2 92.16 High High
Hypersensitivity 5 91.76 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
This compound's unique chemical structure and effect on COX enzyme binding and activity as well as its potency and selectivity may prove useful in treating pain and inflammation.
COX Binding (binding) of associated with pain, inflammation and potency
1) Confidence 0.47 Published 2008 Journal Eur. J. Pharmacol. Section Abstract Doc Link 18457826 Disease Relevance 0.86 Pain Relevance 0.70
Indomethacin inhibits both cyclooxygenase (COX) isoforms, but it may also act via COX-independent targets.
COX Binding (act) of
2) Confidence 0.36 Published 2003 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 12606626 Disease Relevance 0.64 Pain Relevance 0.17
Aspirin and all nonsteroidal anti-inflammatory drugs (NSAIDs) are a chemically heterogeneous group of compounds that share the ability to inhibit the enzyme cyclooxygenase (COX).
COX Neg (inhibit) Binding (inhibit) of associated with aspirin, inflammation and cinod
3) Confidence 0.36 Published 2003 Journal Allergy Asthma Proc Section Abstract Doc Link 12974196 Disease Relevance 0.59 Pain Relevance 0.75
NSAIDs block the activity of both COX isozymes, COX-1 and COX-2, which mediate the enzymatic conversion of arachidonate to prostaglandin H2 (PGH2) and other prostaglandin (PG) metabolites.
COX Neg (block) Binding (activity) of associated with cinod
4) Confidence 0.36 Published 2005 Journal ScientificWorldJournal Section Abstract Doc Link 16113940 Disease Relevance 0.38 Pain Relevance 0.37
Important questions remain regarding relative GI and CV risks: is concomitant aspirin protective when coadministered with COX-2s?
COX Binding (coadministered) of associated with aspirin and cva
5) Confidence 0.36 Published 2006 Journal J. Cardiovasc. Pharmacol. Section Abstract Doc Link 16785830 Disease Relevance 0.96 Pain Relevance 0.77
Based on that background two different approaches were pursued in the search for GI sparing NSAIDs: a) modification of classical NSAIDs by associating them with phospholipids, cyclodextrins, or chemical moieties that release gastroprotective mediators and b) defining novel targets as well as developing new compounds like dual COX/5-LO or mPGES-1 inhibitors.
COX Binding (compounds) of associated with cinod
6) Confidence 0.36 Published 2009 Journal Curr. Med. Chem. Section Abstract Doc Link 19519380 Disease Relevance 0.44 Pain Relevance 0.80
Modulation of the interaction between COX products of the vasculature and platelets underlies both the cardioprotection afforded by aspirin and the cardiovascular hazard which characterises specific inhibitors of COX-2.
COX Binding (interaction) of in platelets associated with aspirin
7) Confidence 0.35 Published 2006 Journal Handb Exp Pharmacol Section Abstract Doc Link 16999220 Disease Relevance 0.10 Pain Relevance 0.29
Modulation of the interaction between COX products of the vasculature and platelets underlies both the cardioprotection afforded by aspirin and the cardiovascular hazard which characterises specific inhibitors of COX-2.
COX Binding (interaction) of in vasculature associated with aspirin
8) Confidence 0.12 Published 2006 Journal Handb Exp Pharmacol Section Abstract Doc Link 16999220 Disease Relevance 0.10 Pain Relevance 0.29

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox